Biocardia, INC Form 4 insider transactions

Peter Altman, President and CEO and a Director of BioCardia, Inc., purchased 1,900 shares of common stock on August 13, 2026 for $0.92 per share.

Peter Altman, President and CEO and a Director of BioCardia, Inc., purchased 5,000 shares of common stock on July 29, 2026 for $0.78 per share.

Peter Altman, President and CEO and a Director of BioCardia, Inc., purchased 500 shares of common stock on July 17, 2026 for $0.83 per share.

Peter Altman, President and CEO and a Director of BioCardia, Inc., purchased 4,300 shares of common stock on July 14, 2026.

BioCardia, Inc. President and CEO Peter Altman acquired a total of 7,500 shares of common stock across three transactions in early July 2026.

BioCardia, Inc. President and CEO Peter Altman reported a transaction involving the sale of 5,400 shares of common stock.

BioCardia, Inc. reports that Director Simon H. Stertzer acquired 8,000 stock options on July 6, 2026.

BioCardia, Inc. reports that Director Marvin Slosman acquired 8,000 stock options on July 6, 2026, as part of his compensation.

BioCardia, Inc. reports on Form 4 detailing stock transactions by President and CEO Peter Altman, including withholding of shares for tax obligations and stock option grants.

BioCardia's Chief Financial Officer, David McClung, reported transactions involving the acquisition of common stock and the exercise of stock options.

BioCardia, Inc. executive Edward M. Gillis reported transactions involving common stock and stock options on July 2, 2026.

BioCardia, Inc. reports that Director Andrew Scott Blank was granted stock options for 8,000 shares.

BioCardia, Inc. director Jim L. Allen acquired 8,000 stock options.

BioCardia, Inc. director Jay M. Moyes acquired 8,000 stock options with an exercise price of $1.20, vesting over one year.

BioCardia, Inc. Director Bill Facteau acquired 8,000 stock options, with vesting contingent on continued service.

BioCardia, Inc. reports that its President and CEO, Peter Altman, acquired 110,625 shares of common stock on June 29, 2026, as part of his compensation.

BioCardia's Chief Financial Officer, David McClung, acquired 60,483 shares of common stock.

BioCardia, Inc. reports a significant acquisition of common stock by Senior Vice President Edward M. Gillis.

BioCardia, Inc. Director Simon H. Stertzer acquired shares in the company through multiple transactions on June 22 and June 23, 2026.

BioCardia, Inc. President and CEO Peter Altman acquired 5,000 shares of common stock at a price of $0.85 per share.

BioCardia, Inc. President and CEO Peter Altman purchased 1,700 shares of common stock across two transactions in May 2026.

BioCardia, Inc. President and CEO Peter Altman purchased 5,700 shares of common stock at a weighted average price of $0.92.

BioCardia, Inc. President and CEO Peter Altman purchased 5,100 shares of common stock at a weighted average price of $1.02.

BioCardia, Inc. President and CEO Peter Altman purchased 5,000 shares of common stock at $1.11 per share.

BioCardia, Inc. President and CEO Peter Altman purchased 1,000 shares of common stock across two transactions.

BioCardia Inc.'s President and CEO, Peter Altman, increased his direct ownership in the company by purchasing additional common stock on March 24 and 25, 2026.

BioCardia's President and CEO, Peter Altman, has filed a Form 4 indicating a planned purchase of 5,000 shares of common stock at $1.13 per share on February 4, 2026, under a Rule 10b5-1 plan.

BioCardia's President and CEO, Peter Altman, acquired an additional 900 shares of common stock in open market transactions.

Peter Altman, BioCardia's President and CEO, increased his direct ownership in the company by acquiring 1,100 shares of common stock over two days.

BioCardia's President and CEO, Peter Altman, reported the vesting of restricted stock units and the grant of new stock options.